Effect of green tea supplementation on blood pressure among overweight and obese adults: A systematic review and meta-analysis

Journal of Hypertension

Volumn 33, Issue 2, 2015, Pages 243-254

  Li, Guowei ^a   Zhang, Yuan ^a   Thabane, Lehana ^a,b   Mbuagbaw, Lawrence ^a   Liu, Aiping ^c   Levine, Mitchell A H ^a,b   Holbrook, Anne ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b ST JOSEPH S HOSPITAL   (Canada)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

blood pressure; green tea; obesity; overweight; systematic review

Indexed keywords

GREEN TEA EXTRACT; PLACEBO; PLANT EXTRACT; TEA;

ABSENCE OF SIDE EFFECTS; ADULT DISEASE; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; COMPARATIVE STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG WITHDRAWAL; HUMAN; MEAN ARTERIAL PRESSURE; META ANALYSIS; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; SUPPLEMENTATION; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TEA; WEIGHT REDUCTION; ADULT; COMPLICATION; DIETARY SUPPLEMENT; DRUG EFFECTS; HYPERTENSION; PHYTOTHERAPY;

ADULT; BLOOD PRESSURE; DIETARY SUPPLEMENTS; HUMANS; HYPERTENSION; OBESITY; OVERWEIGHT; PHYTOTHERAPY; PLANT EXTRACTS; TEA;

EID: 84920870729     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000426     Document Type: Article

References (87)

1. World Health Organization. Obesity. http://www.who.int/topics/obesity/en/. [Updated March 2013, accessed January 2014]
2. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999; 282:1523-1529.
3. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289:76-79.
4. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007; 49:69-75.
5. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006; 113:898-918.
6. Krauss RM, Winston M, Fletcher BJ, Grundy SM. Obesity impact on cardiovascular disease. Circulation 1998; 98:1472-1476.
7. Vital signs: prevalence, treatment, and control of hypertension: United States, 1999-2002 and 2005-2008. MMWR Morb Mortal Wkly Rep 2011; 60:103-108.
8. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010; 303:235-241.
9. Kotchen TA. Obesity-related hypertension: epidemiology, pathophysiology, and clinical management. Am J Hypertens 2010; 23:1170-1178.
10. Kotsis V, Stabouli S, Papakatsika S, Rizos Z, Parati G. Mechanisms of obesity-induced hypertension. Hypertens Res 2010; 33:386-393.
11. Kotsis V, Stabouli S, Papakatsika S, Rizos Z, Parati G. Mechanisms of obesity-induced hypertension. Hypertens Res 2010; 33:386-393.
12. Landsberg L, Aronne LJ, Beilin LJ, Burke V, Igel LI, Lloyd-Jones D, Sowers J. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of The Obesity Society and the American Society of Hypertension. J Clin Hypertens (Greenwich, Conn) 2013; 15:14-33.
13. Mikhail N, Golub MS, Tuck ML. Obesity and hypertension. Prog Cardiovasc Dis 1999; 42:39-58.
14. Vuong QV. Epidemiological evidence linking tea consumption to human health: a review. Crit Rev Food Sci Nutr 2014; 54:523-536.
15. Mukhtar H, Ahmad N. Tea polyphenols: prevention of cancer and optimizing health. Am J Clin Nutr 2000; 71 (6 Suppl):1698S-1702S; [discussion 1703S-1694S].
16. Riemersma RA, Rice-Evans CA, Tyrrell RM, Clifford MN, Lean ME. Tea flavonoids and cardiovascular health. QJM 2001; 94:277-282.
17. Ross JA, Kasum CM. Dietary flavonoids: bioavailability, metabolic effects, and safety. Ann Rev Nutr 2002; 22:19-34.
18. Ihm SH, Jang SW, Kim OR, Chang K, Oak MH, Lee JO, et al. Decaffeinated green tea extract improves hypertension and insulin resistance in a rat model of metabolic syndrome. Atherosclerosis 2012; 224:377-383.
19. Jang HJ, Ridgeway SD, Kim JA. Effects of the green tea polyphenol epigallocatechin-3-gallate on high-fat diet-induced insulin resistance and endothelial dysfunction. Am J Physiol Endocrinol Metab 2013; 305:E1444-E1451.
20. Deka A, Vita JA. Tea and cardiovascular disease. Pharmacol Res 2011; 64:136-145.
21. Johnson R, Bryant S, Huntley AL. Green tea and green tea catechin extracts: an overview of the clinical evidence. Maturitas 2012; 73:280-287.
22. Zheng XX, Xu YL, Li SH, Liu XX, Hui R, Huang XH. Green tea intake lowers fasting serum total and LDL cholesterol in adults: ameta-analysisof 14 randomized controlled trials. Am J Clin Nutr 2011; 94:601-610.
23. Kim A, Chiu A, Barone MK, Avino D, Wang F, Coleman CI, Phung OJ. Green tea catechins decrease total and low-density lipoprotein cholesterol: a systematic review and meta-analysis. J Am Diet Assoc 2011; 111:1720-1729.
24. Savica V, Bellinghieri G, Kopple JD. The effect of nutrition on blood pressure. Ann Rev Nutr 2010; 30:365-401.
25. Yung LM, Leung FP, Wong WT, Tian XY, Yung LH, Chen ZY, et al. Tea polyphenols benefit vascular function. Inflammopharmacology 2008; 16:230-234.
26. Whelton PK, He J, Appel LJ, Cutler JA, Havas S, Kotchen TA, et al. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA 2002; 288:1882-1888.
27. Potenza MA, Marasciulo FL, Tarquinio M, Tiravanti E, Colantuono G, Federici A, et al. EGCG, a green tea polyphenol, improves endothelial function and insulin sensitivity, reduces blood pressure, and protects against myocardial I/R injury in SHR. Am J Physiol Endocrinol Metab 2007; 292:E1378-E1387.
28. Negishi H, Xu J-W, Ikeda K, Njelekela M, Nara Y, Yamori Y. Black and green tea polyphenols attenuate blood pressure increases in strokeprone spontaneously hypertensive rats. J Nutr 2004; 134:38-42.
29. Peters U, Poole C, Arab L. Does tea affect cardiovascular disease? A meta-analysis. Am J Epidemiol 2001; 154:495-503.
30. Arab L, Liu W, Elashoff D. Green and black tea consumption and risk of stroke: a meta-analysis. Stroke 2009; 40:1786-1792.
31. Wang Z-M, Zhou B, Wang Y-S, Gong Q-Y, Wang Q-M, Yan J-J, et al. Black and green tea consumption and the risk of coronary artery disease: a meta-analysis. Am J Clin Nutr 2011; 93:506-515.
32. Hooper L, Kroon PA, Rimm EB, Cohn JS, Harvey I, Le Cornu KA, et al. Flavonoids, flavonoid-rich foods, and cardiovascular risk: a metaanalysis of randomized controlled trials. Am J Clin Nutr 2008; 88: 38-50.
33. Taubert D, Roesen R, Schömig E. Effect of cocoa and tea intake on blood pressure: a meta-analysis. Arch Internal Med 2007; 167: 626-634.
34. Hartley L, Flowers N, Holmes J, Clarke A, Stranges S, Hooper L, Rees K. Green and black tea for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013; 6:CD009934.
35. Onakpoya I, Spencer E, Heneghan C, Thompson M. The effect of green tea on blood pressure and lipid profile: a systematic review and metaanalysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2014; 24:823-836.
36. Brown AL, Lane J, Coverly J, Stocks J, Jackson S, Stephen A, et al. Effects of dietary supplementation with the green tea polyphenol epigallocatechin- 3-gallate on insulin resistance and associated metabolic risk factors: randomized controlled trial. Br J Nutr 2009; 101:886-894.
37. Nagao T, Hase T, Tokimitsu I. A green tea extract high in catechins reduces body fat and cardiovascular risks in humans. Obesity (Silver Spring) 2007; 15:1473-1483.
38. Bogdanski P, Suliburska J, Szulinska M, Stepien M, Pupek-Musialik D, Jablecka A. Green tea extract reduces blood pressure, inflammatory biomarkers, and oxidative stress and improves parameters associated with insulin resistance in obese, hypertensive patients. Nutr Res 2012; 32:421-427.
39. Brown AL, Lane J, Holyoak C, Nicol B, Mayes AE, Dadd T. Health effects of green tea catechins in overweight and obese men: a randomised controlled cross-over trial. Br J Nutr 2011; 106:1880-1889.
40. Basu A, Sanchez K, Leyva MJ, Wu M, Betts NM, Aston CE, Lyons TJ. Green tea supplementation affects body weight, lipids, and lipid peroxidation in obese subjects with metabolic syndrome. J Am Coll Nutr 2010; 29:31-40.
41. Suliburska J, Bogdanski P, Szulinska M, Stepien M, Pupek-Musialik D, Jablecka A. Effects of green tea supplementation on elements, total antioxidants, lipids, and glucose values in the serum of obese patients. Biol Trace Element Res 2012; 149:315-322.
42. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Br Med J (Clinical research ed) 2009; 339:b2535.
43. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions 5.1.0. [updated March 2011] http://handbook.cochrane.org.
44. Li G, Zhang Y, Mbuagbaw L, Holbrook A, Levine M, Thabane L. Effect of green tea supplementation on blood pressure among overweight and obese adults: a protocol for a systematic review. Br Med J Open 2014; 4:e004971.
45. Li G, Mbuagbaw L, Samaan Z, Zhang S, Adachi JD, Papaioannou A, Thabane L. Efficacy of vitamin D supplementation in depression in adults: a systematic review protocol. Syst Rev 2013; 2:64.
46. Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Family Med 2005; 37:360-363.
47. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med 2002; 21:1539-1558.
48. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J (Clinical research ed) 2003; 327:557-560.
49. Boehm K, Borrelli F, Ernst E, Habacher G, Hung SK, Milazzo S, Horneber M. Green tea (Camellia sinensis) for the prevention of cancer. Cochrane Database Syst Rev 2009; 3:CD005004.
50. Harbowy M, Ballentine D. Tea chemistry. Crit Rev Plant Sci 1997; 16:415-480.
51. Wolfram S. Effects of green tea and EGCG on cardiovascular and metabolic health. J Am Coll Nutr 2007; 26:373S-388S.
52. Hodgson JM, Croft KD. Tea flavonoids and cardiovascular health. Molec Aspects Med 2010; 31:495-502.
53. Jurgens TM, Whelan AM, Killian L, Doucette S, Kirk S, Foy E. Green tea for weight loss and weight maintenance in overweight or obese adults. Cochrane Database Syst Rev 2012; 12:CD008650.
54. MacMahon S, Cutler J, Brittain E, Higgins M. Obesity and hypertension: epidemiological and clinical issues. Eur Heart J 1987; 8 (Suppl B):57-70.
55. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Br Med J (Clinical research ed) 2008; 336:924-926.
56. Vlachopoulos C, Alexopoulos N, Dima I, Aznaouridis K, Andreadou I, Stefanadis C. Acute effect of black and green tea on aortic stiffness and wave reflections. J Am Coll Nutr 2006; 25:216-223.
57. Alexopoulos N, Vlachopoulos C, Aznaouridis K, Baou K, Vasiliadou C, Pietri P, et al. The acute effect of green tea consumption on endothelial function in healthy individuals. Eur J Cardiovasc Prevent Rehabil 2008; 15:300-305.
58. Hodgson JM, Puddey IB, Croft KD, Burke V, Mori TA, Caccetta RA-A, Beilin LJ. Acute effects of ingestion of black and green tea on lipoprotein oxidation. Am J Clin Nutr 2000; 71:1103-1107.
59. Thielecke F, Rahn G, Böhnke J, Adams F, Birkenfeld AL, Jordan J, Boschmann M. Epigallocatechin-3-gallate and postprandial fat oxidation in overweight/obese male volunteers: a pilot study. Eur J Clin Nutr 2010; 64:704-713.
60. Hodgson JM, Puddey IB, Burke V, Beilin LJ, Jordan N. Effects on blood pressure of drinking green and black tea. J Hypertens 1999; 17:457-463.
61. Randell RK, Hodgson AB, Lotito SB, Jacobs DM, Boon N, Mela DJ, Jeukendrup AE. No effect of 1 or 7 d of green tea extract ingestion on fat oxidation during exercise. Med Sci Sports Exercise 2013; 45:883-891.
62. Toolsee NA, Aruoma OI, Gunness TK, Kowlessur S, Dambala V, Murad F, et al. Effectiveness of green tea in a randomized human cohort: relevance to diabetes and its complications. BioMed Res Int 2013; doi: 10.1155/2013/412379.
63. Maki KC, Reeves MS, Farmer M, Yasunaga K, Matsuo N, Katsuragi Y, et al. Green tea catechin consumption enhances exercise-induced abdominal fat loss in overweight and obese adults. J Nutr 2009; 139:264-270.
64. Batista GdAP, Cunha CL, Scartezini M, von der Heyde R, Bitencourt MG, Melo SFd. Prospective double-blind crossover study of Camellia sinensis (green tea) in dyslipidemias. Arquivos brasileiros de cardiologia 2009; 93:128-134.
65. Basu A, Du M, Sanchez K, Leyva MJ, Betts NM, Blevins S, et al. Green tea minimally affects biomarkers of inflammation in obese subjects with metabolic syndrome. Nutrition 2011; 27:206-213.
66. Diepvens K, Kovacs E, Vogels N, Westerterp-Plantenga M. Metabolic effects of green tea and of phases of weight loss. Physiol Behav 2006; 87:185-191.
67. Frank J, George TW, Lodge JK, Rodriguez-Mateos AM, Spencer JP, Minihane AM, Rimbach G. Daily consumption of an aqueous green tea extract supplement does not impair liver function or alter cardiovascular disease risk biomarkers in healthy men. J Nutr 2009; 139:58-62.
68. Hill AM, Coates AM, Buckley JD, Ross R, Thielecke F, Howe PR. Can EGCG reduce abdominal fat in obese subjects? J Am Coll Nutr 2007; 26:396S-402S.
69. Hsu C-H, Liao Y-L, Lin S-C, Tsai T-H, Huang C-J, Chou P. Does supplementation with green tea extract improve insulin resistance in obese type 2 diabetics? A randomized, double-blind, and placebocontrolled clinical trial. Alternative Med Rev 2011; 16:157-163.
70. Nantz MP, Rowe CA, Bukowski JF, Percival SS. Standardized capsule of Camellia sinensis lowers cardiovascular risk factors in a randomized, double-blind, placebo-controlled study. Nutrition 2009; 25:147-154.
71. Takase H, Nagao T, Otsuka K, Meguro S, Komikado M, Tokimitsu I. Effects of long-term ingestion of tea catechins on visceral fat accumulation and metabolic syndrome risk in women with abdominal obesity. Jpn Pharmacol Ther 2008; 36:237-245.
72. Takeshita M, Takashima S, Harada U, Shibata E, Hosoya N, Takase H, et al. Effects of long-term consumption of tea catechins-enriched beverage with no caffeine on body composition in humans. Jpn Pharmacol Ther 2008; 36:767-776.
73. Liu CY, Huang CJ, Huang LH, Chen IJ, Chiu JP, Hsu CH. Effects of green tea extract on insulin resistance and glucagon-like peptide 1 in patients with type 2 diabetes and lipid abnormalities: a randomized, doubleblinded, and placebo-controlled trial. PloS One 2014; 9:e91163.
74. Hsu C-H, Tsai T-H, Kao Y-H, Hwang K-C, Tseng T-Y, Chou P. Effect of green tea extract on obese women: a randomized, double-blind, placebo-controlled clinical trial. Clin Nutr 2008; 27:363-370.
75. Bøhn SK, Ward NC, Hodgson JM, Croft KD. Effects of tea and coffee on cardiovascular disease risk. Food Funct 2012; 3:575-591.
76. Sun X, Briel M, Walter SD, Guyatt GH. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. Br Med J (Clinical research ed) 2010; 340:c117.
77. Li G, Mbuagbaw L, Samaan Z, Falavigna M, Zhang S, Adachi JD, et al. Efficacy of vitamin D supplementation in depression in adults: a systematic review. J Clin Endocrinol Metab 2014; 99:757-767.
78. Yokoyama Y, Nishimura K, Barnard ND, Takegami M, Watanabe M, Sekikawa A, et al. Vegetarian diets and blood pressure: a meta-analysis. JAMA Intern Med 2014; 174:577-587.
79. Yung L, Leung F, Wong W, Tian X, Yung L, Chen Z, et al. Tea polyphenols benefit vascular function. Inflammopharmacology 2008; 16:230-234.
80. Moore RJ, Jackson KG, Minihane AM. Green tea (Camellia sinensis) catechins and vascular function. Br J Nutr 2009; 102:1790-1802.
81. Fukino Y, Shimbo M, Aoki N, Okubo T, Iso H. Randomized controlled trial for an effect of green tea consumption on insulin resistance and inflammation markers. J Nutrition Sci Vitaminol 2005; 51:335-342.
82. Shea BJ, Hamel C, Wells GA, Bouter LM, Kristjansson E, Grimshaw J, et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol 2009; 62:1013-1020.
83. Nguyen DM, El-Serag HB. The epidemiology of obesity. Gastroenterol Clin N Am 2010; 39:1-7.
84. Emberson J, Whincup P, Morris R, Walker M, Ebrahim S. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J 2004; 25:484-491.
85. Kain HK, Hinman AT, Sokolow M. Arterial blood pressure measurements with a portable recorder in hypertensive patients I. Variability and correlation with' casual' pressures. Circulation 1964; 30:882-892.
86. Rafey M. Beyond office sphygmomanometry: ways to better assess blood pressure. Cleve Clin J Med 2009; 76:657-662.
87. Riemersma R, Rice-Evans C, Tyrrell R, Clifford M, Lean M. Tea flavonoids and cardiovascular health. QJM 2001; 94:277-282.